The pre-B-cell (clgM) phenotype of childhood ALL comprises about one-fifth of newly diagnosed cases. It has a high frequency of chromosomal translocation, and is closely associated with the t(l;19)(q23;p13). The poor treatment outcome and high-risk features previously ascribed to this phenotype appear to be primarily due to the subset of cases with the t(l;19). Early results of at least one study suggest that aggressive treatment may even nullify the adverse prognostic implication of the t(l;19). Finally, molecular analyses of these cases have yielded exciting new information regarding the pathogenesis of pre-B-cell ALL with the t(l;19), and recombinant DNA technology (polymerase chain reaction) is likely to make molecular diagnosis and detection of minimal residual disease possible in the near future.
No takes yet. Share an insight, caveat, or question.
Crist et al. (1990) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: